Exploring the Relationship between Antioxidant Enzymes, Oxidative Stress Markers, and Clinical Profile in Relapsing-Remitting Multiple Sclerosis

被引:14
|
作者
Bizon, Anna [1 ]
Chojdak-Lukasiewicz, Justyna [2 ]
Budrewicz, Slawomir [2 ]
Pokryszko-Dragan, Anna [2 ]
Piwowar, Agnieszka [1 ]
机构
[1] Wroclaw Med Univ, Fac Pharm, Dept Toxicol, Borowska 211, PL-50556 Wroclaw, Poland
[2] Wroclaw Med Univ, Fac Med, Dept Neurol, Borowska 213, PL-50556 Wroclaw, Poland
关键词
relapsing-remitting multiple sclerosis; oxidative stress; antioxidants; GLUTATHIONE-PEROXIDASE; SUPEROXIDE-DISMUTASE; CATALASE; SELENIUM; ERYTHROCYTES; SERUM;
D O I
10.3390/antiox12081638
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
We aimed to investigate the extent of alterations in the pro/antioxidant balance in the blood of patients with relapsing-remitting multiple sclerosis (RRMS) in relation to drug-modified therapy, gender, disability score, and disease duration. 161 patients (67 men and 94 women, aged 24-69 years, median 43.0) and 29 healthy individuals (9 men and 20 women, aged 25-68 years, median 41.0) were included in the study. We measured the activity of superoxide dismutase (SOD), glutathione peroxidase (GPx), and catalase (CAT) as well as the concentration of interleukin-6 (IL-6), lipid peroxidation parameters (LPO), total oxidant status (TOS), and total antioxidant capacity (TAS). The activity of SOD did not show any significant differences between patients with RRMS and the control group in our study. In contrast, significant decreased GPx activity and increased CAT activity was observed in the blood of patients with RRMS compared to the control group. Additionally, the activity of CAT was influenced by gender and the use of disease-modifying therapies. Disease-modifying therapies also affected the concentration of TOS, TAS, and LPO. Our studies indicated that enhancing GPx activity may be more beneficial to providing potential therapeutic strategies aimed at modulating antioxidant defenses to mitigate oxidative stress in this disease.
引用
收藏
页数:17
相关论文
共 50 条
  • [41] Antioxidative effects of silymarin on the reduction of liver complications of fingolimod in patients with relapsing-remitting multiple sclerosis: A clinical trial study
    Ghiasian, Masoud
    Nafisi, Hamid
    Ranjbar, Akram
    Mohammadi, Younes
    Ataei, Sara
    JOURNAL OF BIOCHEMICAL AND MOLECULAR TOXICOLOGY, 2021, 35 (08)
  • [42] Clinical and MRI predictors of cognitive decline in patients with relapsing-remitting multiple sclerosis: A 2-year longitudinal study
    Dong, Xiaoli
    Xu, Guodong
    Wang, Jia
    Yin, Nan
    Meng, Nan
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2022, 65
  • [43] High-dose vitamin D3 supplementation in relapsing-remitting multiple sclerosis: a randomised clinical trial
    Cassard, Sandra D.
    Fitzgerald, Kathryn C.
    Qian, Peiqing
    Emrich, Susan A.
    Azevedo, Christina J.
    Goodman, Andrew D.
    Sugar, Elizabeth A.
    Pelletier, Daniel
    Waubant, Emmanuelle
    Mowry, Ellen M.
    ECLINICALMEDICINE, 2023, 59
  • [44] Safety and tolerability of fingolimod in patients with relapsing-remitting multiple sclerosis: results of an open-label clinical trial in Italy
    Alice Laroni
    Davide Brogi
    Vincenzo Brescia Morra
    Leonello Guidi
    Carlo Pozzilli
    Giancarlo Comi
    Alessandra Lugaresi
    Renato Turrini
    Debora Raimondi
    Antonio Uccelli
    Giovanni Luigi Mancardi
    Neurological Sciences, 2017, 38 : 53 - 59
  • [45] Long-term effects of natalizumab on MRI activity and clinical outcomes in Japanese patients with relapsing-remitting multiple sclerosis
    Takahiko Saida
    Qi Hao
    Michihiro Kanda
    Yumiko Tani
    BMC Neurology, 23
  • [46] Sirtuins and Metabolism Biomarkers in Relapsing-Remitting and Secondary Progressive Multiple Sclerosis: a Correlation Study with Clinical Outcomes and Cognitive Impairments
    Foolad, Forough
    Samadi-Bahrami, Zahra
    Khodagholi, Fariba
    Nabavi, Seyed Massood
    Moore, G. R. Wayne
    Javan, Mohammad
    MOLECULAR NEUROBIOLOGY, 2024, 61 (06) : 3442 - 3460
  • [47] Exploiting relationships between outcomes in Bayesian multivariate network meta-analysis with an application to relapsing-remitting multiple sclerosis
    Waddingham, Ed
    Matthews, Paul M.
    Ashby, Deborah
    STATISTICS IN MEDICINE, 2020, 39 (24) : 3329 - 3346
  • [48] Genetic differences between primary progressive and relapsing-remitting multiple sclerosis: The impact of immune-related genes variability
    Kiselev, Ivan
    Bashinskaya, Vitalina
    Baulina, Natalia
    Kozin, Maxim
    Popova, Ekaterina
    Boyko, Alexey
    Favorova, Olga
    Kulakov, Olga
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2019, 29 : 130 - 136
  • [49] Mitoxantrone in relapsing-remitting and rapidly progressive multiple sclerosis: Ten-year clinical outcomes post-treatment with mitoxantrone
    Foo, E. C.
    Russell, M.
    Lily, O.
    Ford, H. L.
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2020, 44
  • [50] Evidence for possible role of melatonin in reducing oxidative stress in multiple sclerosis through its effect on SIRT1 and antioxidant enzymes
    Emamgholipour, Solaleh
    Hossein-nezhad, Arash
    Sahraian, Mohammad Ali
    Askarisadr, Fatemeh
    Ansari, Mohammad
    LIFE SCIENCES, 2016, 145 : 34 - 41